Loading
The IL-11 receptor was the target of oprelvekin, the first drug approved to prevent the severe platelet falls that chemotherapy causes; the drug was withdrawn in 2011 and thrombopoietin agonists took over the problem. This dossier gathers the 1 product (0 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A cytokine receptor of the IL-6 family; ligand binding recruits gp130 and activates JAK-STAT3 signalling in megakaryocytes, epithelial cells and fibroblasts.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: IL-11 receptor on platelet precursors. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Withdrawn or failed |
|---|---|
| Recombinant interleukin-11, subcutaneous injection 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 2 | Completed | The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia | - | ||
| 2 | Completed | Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"IL-11 receptor alpha" OR ABSTRACT:"IL-11 receptor alpha" OR TITLE:"IL11RA" OR ABSTRACT:"IL11RA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL-11 receptor alpha, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/il11ra.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/il11ra.json. Licence CC BY-NC 4.0.